| |
Latest 10 SEC filings (by transaction date) for CPRX within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 10/24 | Apr 8/24 | Tierney David S | Direct Ownership | Options to purchase common stock | M - Exercise or conversion exempt under rule 16b-3 | 25,000 | |
Apr 10/24 | Apr 8/24 | Tierney David S | Direct Ownership | Common stock, par value $0.001 per share | S - Open market or private sale | -25,000 | $15.68 |
Apr 10/24 | Apr 8/24 | Tierney David S | Direct Ownership | Common stock, par value $0.001 per share | M - Exercise or conversion exempt under rule 16b-3 | 25,000 | $4.01 |
Mar 28/24 | Mar 27/24 | Elsbernd Brian | Direct Ownership | Common stock, par value $0.001 per share | S - Open market or private sale | -25,000 | $16.44 |
Feb 16/24 | Feb 15/24 | Tierney David S | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -4,000 | |
Feb 16/24 | Feb 15/24 | Tierney David S | Direct Ownership | Common Stock, Par Value $0.001 per share | M - Exercise or conversion exempt under rule 16b-3 | 4,000 | |
Feb 16/24 | Feb 15/24 | Sundaram Preethi | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -16,667 | |
Feb 16/24 | Feb 15/24 | Sundaram Preethi | Direct Ownership | Common Stock, par value $0.001 per share | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -6,025 | |
Feb 16/24 | Feb 15/24 | Sundaram Preethi | Direct Ownership | Common Stock, par value $0.001 per share | M - Exercise or conversion exempt under rule 16b-3 | 16,667 | |
Feb 16/24 | Feb 15/24 | O'Keeffe Charles B | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -4,000 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for CPRX within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 10/24 | Apr 8/24 | Tierney David S | Direct Ownership | Options to purchase common stock | M - Exercise or conversion exempt under rule 16b-3 | 25,000 | |
Apr 10/24 | Apr 8/24 | Tierney David S | Direct Ownership | Common stock, par value $0.001 per share | S - Open market or private sale | -25,000 | $15.68 |
Apr 10/24 | Apr 8/24 | Tierney David S | Direct Ownership | Common stock, par value $0.001 per share | M - Exercise or conversion exempt under rule 16b-3 | 25,000 | $4.01 |
Mar 28/24 | Mar 27/24 | Elsbernd Brian | Direct Ownership | Common stock, par value $0.001 per share | S - Open market or private sale | -25,000 | $16.44 |
Feb 16/24 | Feb 15/24 | Tierney David S | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -4,000 | |
Feb 16/24 | Feb 15/24 | Tierney David S | Direct Ownership | Common Stock, Par Value $0.001 per share | M - Exercise or conversion exempt under rule 16b-3 | 4,000 | |
Feb 16/24 | Feb 15/24 | Sundaram Preethi | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -16,667 | |
Feb 16/24 | Feb 15/24 | Sundaram Preethi | Direct Ownership | Common Stock, par value $0.001 per share | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -6,025 | |
Feb 16/24 | Feb 15/24 | Sundaram Preethi | Direct Ownership | Common Stock, par value $0.001 per share | M - Exercise or conversion exempt under rule 16b-3 | 16,667 | |
Feb 16/24 | Feb 15/24 | O'Keeffe Charles B | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -4,000 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Intra-Cellular Therapies (OQ:ITCI) |
Apellis Pharmaceuticals (OQ:APLS) |
Biomarin Pharmaceutical (OQ:BMRN) |